Evaluation of Natureheme-iron on Iron Absorption Effect and Anti-oxidation Functions
Evaluation of Natureheme-iron on Iron Absorption Effect and Anti-oxidation Functions- a Double-blind, Randomized, Placebo-controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Eligible subjects were anemia men or women aged over 20 years old with Hb<=12 g/dl.
Exclusion Criteria:
- Subjects were excluded if subjects had a history of major cardiovascular disease, severe liver dysfunction, insulin-dependent diabetes mellitus or stroke. Subjects were also excluded if they routinely consumed alcohol, were pregnant or unable to comprehend study instructions.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Natureheme-iron
Subjects receive 2 capsules per day containing either 1000 mg Fe.
|
An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects.
Consenting eligible subjects were receive 2 capsules per day containing either 1000 mg Fe of similar appearance for 12 weeks.
The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended.
During each study visit, fasting blood samples were collected and anthropometric measurements were performed.
Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
|
|
Placebo Comparator: Placebo
Subjects receive 2 capsules per day containing starch placebo of similar appearance.
|
An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects.
Consenting eligible subjects were receive 2 capsules per day containing either 1000 mg starch placebo of similar appearance for 12 weeks.
The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended.
During each study visit, fasting blood samples were collected and anthropometric measurements were performed.
Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
|
|
Active Comparator: supplement
Subjects receive 1 capsule per day containing either 100 mg Fe.
|
An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects.
Consenting eligible subjects were receive 1 capsule per day containing either 100 mg Fe of similar appearance for 12 weeks.
The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended.
During each study visit, fasting blood samples were collected and anthropometric measurements were performed.
Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The Hemoglobin of the Subjects at Baseline and 6 Weeks
Time Frame: 6 weeks
|
The Hb (g/dl) measure at baseline and 6 weeks and compare the value at 6 weeks minus value at baseline.
|
6 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The Changes of Serum Ferritin of the Subjects.
Time Frame: 6 weeks
|
values change of serum ferritin (ng/ml) between before to after 6 weeks
|
6 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- CS14135
- MOST 104-2622-E-040-002 -CC2 (Other Grant/Funding Number: Ministry of Science and Technology)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.